Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
On June 26, 2020, AbbVie (NYSE: ABBV) and Molecular Partners announced that the FDA issued a Complete Response Letter for the Biologics License Application (BLA) of Abicipar pegol, a treatment for neovascular (wet) age-related macular degeneration (nAMD). The FDA cited an unfavorable benefit-risk ratio due to high rates of intraocular inflammation associated with the treatment. AbbVie plans to discuss next steps with the FDA to address these concerns.
AbbVie (NYSE: ABBV) announced FDA review of a supplemental New Drug Application for IMBRUVICA (ibrutinib) in combination with rituximab to treat Waldenström's macroglobulinemia (WM). This application is based on over five years of data from the Phase 3 iNNOVATE clinical trial. IMBRUVICA, the only FDA-approved treatment for WM, was initially approved in 2015 and further expanded in 2018 for combination therapy. The iNNOVATE study involved 150 patients and assessed progression-free survival rates among other outcomes. Presentations of the long-term data are planned for future medical congresses.
AbbVie announced that upadacitinib (15 mg and 30 mg) met co-primary endpoints in the Phase 3 Measure Up 1 study for treating moderate to severe atopic dermatitis in adults and adolescents. At week 16, 70% and 80% of patients achieved EASI 75 with upadacitinib versus 16% in the placebo group. Additionally, 48% and 62% achieved vIGA-AD scores of clear or almost clear. Significant and rapid reductions in itch were also noted, with no new safety risks compared to existing data for RINVOQ. Full results will be shared in future medical forums.
On June 17, 2020, AbbVie (NYSE: ABBV) declared a quarterly cash dividend of $1.18 per share, payable on August 14, 2020 to stockholders of record as of July 15, 2020. Since its inception in 2013, AbbVie has increased its dividend by 195 percent. The company is a member of the S&P Dividend Aristocrats Index, recognizing firms that have raised dividends for at least 25 consecutive years. AbbVie's mission focuses on innovative medicines across various therapeutic areas, including immunology and oncology.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has received FDA approval for JUVÉDERM® VOLUMA™ XC, the first and only injectable filler for chin augmentation in adults over 21. This approval adds to its existing indication for cheek augmentation, enhancing its market presence as the leading product in the JUVÉDERM® portfolio. The clinical study demonstrated its safety and efficacy, with high patient satisfaction reported. This innovation reflects Allergan's commitment to meeting the growing demand for facial symmetry and harmony among patients.